Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 243-258

  Mostaghel, Elahe A ^a   Nelson, Peter S ^a  

^a USA   (United States)

Author keywords

androgen metabolism; castration resistant; hormone therapy; intracrinology; metastatic; prostate cancer; steroidogenesis

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 5 INHIBITOR; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; ABIRATERONE; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CELECOXIB; CINNAMIC ACID DERIVATIVE; CORTICOSTEROID; CYTOCHROME P450 17A INHIBITOR; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DUTASTERIDE; EFENAMIC ACID; FINASTERIDE; FLUTAMIDE; GLUTETHIMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INDOMETACIN; KETOCONAZOLE; MINERALOCORTICOID; N (4 CHLOROBENZOYL)MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID SULFATASE INHIBITOR; UNINDEXED DRUG; VN 124 1;

ADRENAL INSUFFICIENCY; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GENE EXPRESSION REGULATION; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LYMPH NODE METASTASIS; NONHUMAN; ORCHIECTOMY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOSYNTHETIC PATHWAYS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; PARACRINE COMMUNICATION; PROSTATE; PROSTATIC NEOPLASMS;

EID: 42949144171     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.003     Document Type: Review

References (62)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians 22 4 (1972) 232-240
2. Forti G., Salerno R., Moneti G., et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. The Journal of Clinical Endocrinology and Metabolism 68 2 (1989) 461-468
3. Mohler J.L., Gregory C.W., Ford III O.H., et al. The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 2 (2004) 440-448
4. Nishiyama T., Hashimoto Y., and Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 10 21 (2004) 7121-7126
5. Geller J., Liu J., Albert J., et al. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clinical Endocrinology 26 2 (1987) 155-161
6. Scher H.I., Buchanan G., Gerald W., et al. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer 11 3 (2004) 459-476
7. Belanger B., Belanger A., Labrie F., et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry 32 5 (1989) 695-698
8. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 5 (2006) 2815-2825
9. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 1 (2004) 217-227
10. Liu J., Geller J., Albert J., et al. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. The Journal of Clinical Endocrinology and Metabolism 61 1 (1985) 129-133
11. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry 23 5B (1985) 833-841
12. Page S.T., Lin D.W., Mostaghel E.A., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. The Journal of Clinical Endocrinology and Metabolism 91 10 (2006) 3850-3856
13. Mizokami A., Koh E., Fujita H., et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research 64 2 (2004) 765-771
14. Nishiyama T., Ikarashi T., Hashimoto Y., et al. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. The Journal of Urology 178 4 Pt 1 (2007) 1282-1288 [discussion 1288-1289]
15. Montgomery B., Mostaghel E., Vessella R., et al. Androgen synthesis in castration-adapted metastatic prostate cancer. ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology 25 No. 18S (2007) 98
16. Gregory C.W., Johnson Jr. R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 7 (2001) 2892-2898
17. van Weerden W.M., van Steenbrugge G.J., van Kreuningen A., et al. Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. The Journal of Steroid Biochemistry and Molecular Biology 37 6 (1990) 903-907
18. Mostaghel E.A., Page S.T., Lin D.W., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research 67 10 (2007) 5033-5041
19. Ryan C.J., Smith A., Lal P., et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 68 4 (2006) 834-839
20. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 1 (2004) 33-39
21. Small E.J., and Ryan C.J. The case for secondary hormonal therapies in the chemotherapy age. The Journal of Urology 176 6 (2006) S66-S71
22. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 2 (2002) 361-376
23. Klotz L., and Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clinical Prostate Cancer 3 4 (2005) 215-219
24. Labrie F. Adrenal androgens and intracrinology. Seminars in Reproductive Medicine 22 4 (2004) 299-309
25. Bruchovsky N. Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology 89 5 (1971) 1212-1222
26. Schiller C.D., Schneider M.R., Hartmann H., et al. Growth-stimulating effect of adrenal androgens on the R3327 dunning prostatic carcinoma. Urological Research 19 1 (1991) 7-13
27. Harper M.E., Pike A., Peeling W.B., et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. The Journal of Endocrinology 60 1 (1974) 117-125
28. Klein H., Bressel M., Kastendieck H., et al. Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. American Journal of Clinical Oncology 11 Suppl. 2 (1988) S30-S36
29. Miyamoto H., Yeh S., Lardy H., et al. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 95 19 (1998) 11083-11088
30. Acevedo H.F., and Goldzieher J.W. The metabolism of [14C] progesterone by hypertrophic and carcinomatous human prostate tissue. Biochimica et Biophysica Acta 111 1 (1965) 294-298
31. Attard G., Yap T.A., Reid A.H., et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (a), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology 25 No. 18S (2007) 5063
32. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism 15 9 (2004) 432-438
33. Luo J., Dunn T.A., Ewing C.M., et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 57 2 (2003) 134-139
34. Titus M.A., Gregory C.W., Ford III O.H., et al. Steroid 5{alpha}-reductase isozymes I and II in recurrent prostate cancer. Clinical Cancer Research 11 12 (2005) 4365-4371
35. Thomas L.N., Douglas R.C., Lazier C.B., et al. Levels of 5[alpha]-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. The Journal of Urology 179 1 (2008) 147-151
36. Koh E., Noda T., Kanaya J., et al. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 2 (2002) 154-159
37. Fung K.M., Samara E.N., Wong C., et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrine-Related Cancer 13 1 (2006) 169-180
38. Zha S., Ferdinandusse S., Hicks J.L., et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63 4 (2005) 316-323
39. Penning T.M., Bauman D.R., Jin Y., et al. Identification of the molecular switch that regulates access of 5[alpha]-DHT to the androgen receptor. Adrenal/Molecular Steroidogenesis Conference 2006. Molecular and Cellular Endocrinology 265-266 (2007) 77-82
40. Ji Q., Chang L., Stanczyk F.Z., et al. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Research 67 3 (2007) 1361-1369
41. Attard G., Belldegrun A.S., and de Bono J.S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International 96 9 (2005) 1241-1246
42. Handratta V.D., Vasaitis T.S., Njar V.C.O., et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry 48 8 (2005) 2972-2984
43. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer 90 12 (2004) 2317-2325
44. Ryan C.J., Rosenberg J., Lin A., et al. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-lyase inhibitor in androgen-independent prostate cancer (AIPC). ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology 25 No. 18S (2007) 5064
45. Ryan C.J., Halabi S., Ou S.S., et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. Clinical Cancer Research 13 7 (2007) 2030-2037
46. Culig Z., Hobisch A., Cronauer M.V., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology 7 12 (1993) 1541-1550
47. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Journal of Clinical Oncology 22 6 (2004) 1025-1033
48. Berube M., Laplante Y., and Poirier D. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase. Medicinal Chemistry 2 4 (2006) 329-347
49. Lorenzi MV, Rizzo CA, You D, et al. In vivo suppression of testosterone biosynthesis with a novel series of non-steroidal 17{beta}-hydroxysteroid dehydrogenase type III (17{beta}-HSD3) inhibitors. In: Proceedings of the 96th annual meeting of the American Association for Cancer Research; 2005 April 1. p. 605-a. [Abstract 2573].
50. Bauman D.R., Rudnick S.I., Szewczuk L.M., et al. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes. Molecular Pharmacology 67 1 (2005) 60-68
51. Byrns M.C., Steckelbroeck S., and Penning T.M. An indomethacin analogue, n-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochemical Pharmacology 75 2 (2008) 484-493
52. Krazeisen A., Breitling R., Moller G., et al. Phytoestrogens inhibit human 17[beta]-hydroxysteroid dehydrogenase type 5. Molecular and Cellular Endocrinology 171 1-2 (2001) 151-162
53. Brozic P., Golob B., Gomboc N., et al. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (akr1c3). Molecular and Cellular Endocrinology 248 1-2 (2006) 233-235
54. Simard J., Ricketts M.-L., Gingras S., et al. Molecular biology of the 3{beta}-hydroxysteroid dehydrogenase/{delta}5-{delta}4 isomerase gene family. Endocrine Reviews 26 4 (2005) 525-582
55. Thomas J.L., Boswell E.L., Scaccia L.A., et al. Identification of key amino acids responsible for the substantially higher affinities of human type 1 3{beta}-hydroxysteroid dehydrogenase/isomerase (3{beta}-HSD1) for substrates, coenzymes, and inhibitors relative to human 3{beta}-HSD2. The Journal of Biological Chemistry 280 22 (2005) 21321-21328
56. Makridakis N., and Reichardt J.K. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: Comparison of finasteride and dutasteride. Journal of Molecular Endocrinology 34 3 (2005) 617-623
57. Titus M., Li Y., Kawinski E., et al. Biochemical and pharmacological evidence for a third isozyme of steroid 5a-reductase in prostate cancer. American Urological Association, Anaheim (CA) (2007) 268
58. Stanway S.J., Purohit A., Woo L.W., et al. Phase I study of STX 64 (667 coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clinical Cancer Research 12 5 (2006) 1585-1592
59. Klein H., Molwitz T., and Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: Characterization and quantification of the enzyme in epithelium and stroma. Journal of Steroid Biochemistry 33 2 (1989) 195-200
60. Nakamura Y., Suzuki T., Fukuda T., et al. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate 66 9 (2006) 1005-1012
61. Shah R.B., Mehra R., Chinnaiyan A.M., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Research 64 24 (2004) 9209-9216
62. Singh P., Uzgare A., Litvinov I., et al. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer 13 3 (2006) 653-666